IAM Stock Forecast: Iambic Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$13
−8.06% on the day

The 4 Wall Street analysts covering Iambic Therapeutics, Inc. hold a median 12-month price target of $26 — +98.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 1 of 100 as at 21 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$621.4M
Ticker Nerd rank
1/ 100
Median analyst target
$26
Analysts covering
4
Total return, dividends reinvested
1W
+0.1%
1M
−18.1%
From high
−44.9%
From low
+28.9%
$10
$24
Range since 15 Oct 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Iambic Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
1/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
33
Growth
10
Value
10
Accruals
5
Volatility
4
Quality
3
Issuance
2
Momentum
1

Revisions (33): Analysts have, on balance, been raising their forecasts.

Momentum (1): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

IAM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IAM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 15 Oct 2026Adjusted close, US dollars
$10$15$20$25$30$35Oct 26Oct 26Nov 26Nov 26Nov 26IAMHigh $35Median $26Low $22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4
Buy
0
Hold
0
Sell
$22
Low
$26
Median
$35
High

The green dot is the last close — the median target sits +98.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 Nov 2026JefferiesInitiatesBuy$35
9 Nov 2026B of A SecuritiesInitiatesBuy$30
9 Nov 2026CitigroupInitiatesBuy$22
9 Nov 2026JP MorganInitiatesOverweight$22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IAM.

Market Radar

This page is one stock. Monday covers all of them.

IAM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

IAM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

IAM vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100Oct 26Oct 26Nov 26Nov 26Nov 26IAMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IAM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
34.0×

Cheaper than 6% of US stocks

Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
224.7%

Higher than 96% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
—
Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Iambic Therapeutics, Inc. has a market value of $621.4M and an enterprise value of $528.0M.

  • Shares outstanding: 47.4M.

  • Iambic Therapeutics, Inc. employs 171 people.

market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

IAM and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IAMIambic Therapeutics, Inc.$621.4M1
ABUSArbutus Biopharma Corp.$616.2M82
KURAKura Oncology, Inc.$613.4M53
OLMAOlema Oncology, Inc.$611.8M25
JANXJanux Therapeutics, Inc.$606.3M73
SGMTSagimet Biosciences, Inc.$638.7M35
PRMEPrime Medicine, Inc.$643.9M63

Take a look at IAM’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Iambic Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about IAM

What is the IAM stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Iambic Therapeutics, Inc. have a median 12-month price target of $26, with estimates ranging from $22 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IAM stock a buy right now?

Of the 4 analysts covering Iambic Therapeutics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Iambic Therapeutics, Inc. 1 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IAM?

As at 21 Nov 2026, Iambic Therapeutics, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (33 of 100).

Will IAM stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +98.3% from the last close, and Ticker Nerd's factor model ranks Iambic Therapeutics, Inc. 1 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IAM stock forecast for 2030?

No analyst covering Iambic Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IAM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $35 over the next 12 months.

What does Iambic Therapeutics, Inc. do?

Iambic Therapeutics, Inc. is a clinical-stage biotechnology and life sciences company developing small-molecule medicines through an AI-driven drug discovery platform. Its molecular superintelligence approach combines proprietary artificial intelligence with automated, scalable chemistry and biology experiments to identify drug candidates, refine their characteristics, and support development across therapeutic areas.

Company

About Iambic Therapeutics, Inc.

Iambic Therapeutics, Inc. is a clinical-stage biotechnology and life sciences company developing small-molecule medicines through an AI-driven drug discovery platform. Its molecular superintelligence approach combines proprietary artificial intelligence with automated, scalable chemistry and biology experiments to identify drug candidates, refine their characteristics, and support development across therapeutic areas. The company’s current pipeline includes IAM1363, a selective HER2 inhibitor being evaluated in an early-stage clinical trial for patients with HER2-altered solid tumors, as well as preclinical programs targeting KIF18A and CDK2/4. Iambic also provides technology capabilities centered on molecular design, predictive modeling, and experimental validation, including its Enchant and NeuralPLexer systems. Based in San Diego, California, Iambic operates at the intersection of biotechnology, computational science, and pharmaceutical research. Its business model and platform position it within the growing AI-enabled drug discovery market, where advanced computation and laboratory automation are used to improve the identification and optimization of potential therapeutics.

CEO Dr. Thomas Miller Ph.D. · 171 employees · United States · https://www.iambic.ai